The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Sep. 19, 8:49 AM

Slide #22. Trillium Therapeutics Inc. Secondary Offering

Company: Trillium Therapeutics Inc. (NASDAQ:TRIL)
Date announced: 9/9/2020
Shares Offered: 10,000,000
Date of Pricing: 9/10/2020
Price Per Share: $13.00
Secondary Offering Details: Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of up to 8,500,000 common shares (the "Common Shares") of the Company (the "Offering"). In addition, Trillium intends to grant the underwriters a 30-day option to purchase up to an additional number of Common Shares equal to 15% of the Common Shares offered in the Offering. -updated 9/10- Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 10,000,000 common shares (the "Common Shares") of the Company (the "Offering"). The Common Shares are being sold at a public offering price of US$13.00 per Common Share. In connection with the Offering, Trillium has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 Common Shares.

Trillium Therapeutics is a Canadian public company developing stem cell-based therapies for cell therapy and regenerative medicine from academic sources for the purpose of commercialization.
Open the TRIL Page at The Online Investor »

Company Name: 
Trillium Therapeutics Inc
Website: 
www.trilliumtherapeutics.com
Sector: 
Biotechnology
 

Open the TRIL Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes


Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.